Inhalable Bifunctional sEH/COX-2 Inhibitors for Treatment of Asthma

Time: 1:30 pm
day: Conference Day 2


  • Developing inhalable bifunctional sEH/COX-2 small molecule inhibitors with novel mechanisms of action to treat Asthma
  • Asthma affects over 300 million people worldwide and up to 55% of these patients experience recurrent episodes of bronchospasm despite long-acting beta-agonists plus high-dose inhaled or oral corticosteroids
  • Chronic use of corticosteroids can lead to immune suppression, CVD risk, glaucoma, bone loss and myopathy, while alternative new therapies including biologics are expensive and cause adverse side effects